Clinical progress in MSC-based therapies for the management of severe COVID-19. (December 2022)

• Record Type: Journal Article
• Authors: Rossello-Gelabert, Maria; Gonzalez-Pujana, Ainhoa; Igartua, Manoli; Santos-Vizcaino, Edorta; Hernandez, Rosa Maria
• Is Part Of: Cytokine & growth factor reviews. Volume 68(2022)
• Page Start: 25
• Page End: 36
• Publication Date: 2022-12
• Subjects: COVID-19 Coronavirus Disease of 2019 -- MSCs mesenchymal stromal cells -- ARDS acute respiratory distress syndrome -- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 -- NIH national institutes of health -- EVs extracellular vesicles -- FDA food and drug administration -- IL-1β interleukin-1β -- IL-2 interleukin-2 -- IL-10 interleukin-10 -- IFN-γ interferon-γ -- TNF-α tumor necrosis factor-α -- IP-10 inducible protein 10 -- GM-CSF granulocyte macrophage-colony stimulating factor -- MCP-1 monocyte chemoattractant protein-1 -- CRP C-reactive protein -- LDH lactate dehydrogenase -- AST aspartate aminotransferase -- ALT alanine aminotransferase -- IL-6 interleukin-6 -- IL-1 interleukin-1 -- TNF tumor necrosis factor -- ACE2 angiotensin converting enzyme 2 -- S protein spike -- AT2 type 2 alveolar cells of the lungs -- FGF fibroblast growth factor -- TGF transforming growth factor -- VEGF vascular endothelial growth factor -- NK natural -- DCs dendritic cells -- BALF bronchoalveolar lavage fluid -- IL-7 interleukin 7 -- G-CSF granulocyte colony-stimulating factor -- NETs Neutrophil Extracellular Traps -- RF respiratory failure -- ROS reactive oxygen species -- CD cluster of differentiation -- TLR toll-like receptors -- LPS lipopolysaccharide -- IDO indoleamine 2, 3-dioxygenase -- NO nitric oxide -- STAT3 signal transducer activators of transcription-3 -- IL1Ra Interleukin-1 receptor antagonist -- TSG-6 TNF-α-stimulating gene 6 -- MAPK mitogen-activated protein kinase -- NF-κB nuclear factor-kappa B -- IL1-α interleukin 1-α -- IL1-β interleukin 1-β -- IL-7 interleukin-7 -- IL-8 interleukin 8 -- IL-9 interleukin -- miRNA microRNA -- PGE2 prostaglandin E2 -- TGF-β1 transforming growth factor-β1 -- HGF hepatocyte growth factor -- KGF keratinocyte growth factor -- Fas-L Fas ligands -- PD-1 programmed cell death protein 1 -- PD-L1 programmed death ligand-1 -- cAMP cyclic adenosine monophosphate -- IL-2R IL-2 receptor -- FOXP3 + forkhead box P3 + -- Treg regulatory T cell -- Gal-1 galectin-1 -- Gal-3 galectin-3 -- Gal-9 galectin-9 -- HLA human leukocyte antigen -- MHC major histocompatibility complex -- IL-4 interleukin-4 -- GvHD acute graft-versus-host disease -- UC-MSCs umbilical cord derived MSCs -- ICU intensive care unit -- PLX-PAD placental expanded -- MIS-C multisystem inflammatory syndrome in children -- BM-MSCs bone marrow derived MSCs -- AT-MSCs Adipose Tissue derived Mesenchymal Stromal Cells -- Allo-MSCs Allogeneic Mesenchymal Stromal Cells -- WJ-MSCs Wharton's Jelly–derived Mesenchymal Stromal Cells -- HB-AT-MSCs Hope Biosciences autologous adipose-derived mesenchymal stromal cells -- DW-MSCs Daewoong Pharmaceutical's Mesenchymal Stromal Cells -- DSCs Placenta-derived decidua stromal cells -- PL-MSCs Placental-derived Mesenchymal Stromal Cells, MB-MSCs, Menstrual blood-derived Mesenchymal Stromal Cells -- IV intravenous -- Ld Low dose -- Hd High dose -- IMV Invasive mechanical ventilation -- adm administration -- bw Body weight -- Allo allogeneic -- INH inhalation -- NVs nanovesicles; Mesenchymal stromal cells -- COVID-19 -- SARS-CoV-2 -- Cytokine storm -- Immunomodulation -- Secretome; Cytokines -- Periodicals; 571.84
• DOI: 10.1016/j.cytogfr.2022.07.002
• Languages: English
• ISSNs: 1359-6101

Abstract

Abstract: Considering the high impact that severe Coronavirus disease 2019 (COVID-19) cases still pose on public health and their complex pharmacological management, the search for new therapeutic alternatives is essential. Mesenchymal stromal cells (MSCs) could be promising candidates as they present important immunomodulatory and anti-inflammatory properties that can combat the acute severe respiratory distress syndrome (ARDS) and the cytokine storm occurring in COVID-19, two processes that are mainly driven by an immunological misbalance. In this review, we provide a comprehensive overview of the intricate inflammatory process derived from the immune dysregulation that occurs in COVID-19, discussing the potential that the cytokines and growth factors that constitute the MSC-derived secretome present to treat the disease. Moreover, we revise the latest clinical progress made in the field, discussing the most important findings of the clinical trials conducted to date, which follow 2 different approaches: MSC-based cell therapy or the administration of the secretome by itself, as a cell-free therapy. Highlights: Provide a comprehensive overview of the intricate inflammatory process derived from the immune dysregulation in COVID-19. Discuss the potential of the cytokines and growth factors that constitute MSC-derived secretome to treat the disease. Revise the latest clinical progress made in the field, discussing the most important findings conducted to date.